Compare AstraZeneca plc (AZN) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares China Large-Cap ETF — how do they compare? AstraZeneca plc trades at $167.12 (market cap $253.13B), while iShares China Large-Cap ETF trades at $34.12. The key difference: AstraZeneca plc pays a 1.92% dividend while iShares China Large-Cap ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| AZN | FXI | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | — |
52-Week High | $209.48 | $41.75 |
52-Week Low | $137.44 | $31.59 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
FXI trades at $33.44, down slightly (-0.12%) on the day, with technical indicators showing mixed signals between bullish moving averages and neutral oscillators. The ETF benefits from China's aggressive AI and EV investments, including a $295 billion AI infrastructure plan and 30% NEV fleet target by 2030. Recent manufacturing rebounds and strong export data provide fundamental support, though geopolitical tensions with the US pose headwinds.
Outlook remains cautiously optimistic given China's tech investment surge and manufacturing recovery. Key opportunities include exposure to AI hardware exports and domestic EV growth, while risks center on US-China trade restrictions and potential valuation pressures. The ETF offers diversified China large-cap access but requires monitoring of geopolitical developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
